Last Updated: June 5, 2026

DESVENLAFAXINE SUCCINATE Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Desvenlafaxine Succinate patents expire, and what generic alternatives are available?

Desvenlafaxine Succinate is a drug marketed by Actavis Labs Fl, Alembic, Hikma, Lupin Ltd, Macleods Pharms Ltd, Pharmobedient, Platinum, Rubicon Research, Yichang Humanwell, and Zydus Pharms. and is included in eleven NDAs.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Desvenlafaxine Succinate

A generic version of DESVENLAFAXINE SUCCINATE was approved as desvenlafaxine succinate by ALEMBIC on June 29th, 2015.

  Start Trial

AI Deep Research
Questions you can ask:
  • What is the 5 year forecast for DESVENLAFAXINE SUCCINATE?
  • What are the global sales for DESVENLAFAXINE SUCCINATE?
  • What is Average Wholesale Price for DESVENLAFAXINE SUCCINATE?
Recent Clinical Trials for DESVENLAFAXINE SUCCINATE

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jiangsu Province Nanjing Brain HospitalNA
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Phase 3
Korea Cancer Center HospitalPhase 4

See all DESVENLAFAXINE SUCCINATE clinical trials

Medical Subject Heading (MeSH) Categories for DESVENLAFAXINE SUCCINATE
Paragraph IV (Patent) Challenges for DESVENLAFAXINE SUCCINATE
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
PRISTIQ Extended-release Tablets desvenlafaxine succinate 25 mg 021992 1 2015-05-08
PRISTIQ Extended-release Tablets desvenlafaxine succinate 50 mg and 100 mg 021992 12 2012-02-29

US Patents and Regulatory Information for DESVENLAFAXINE SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204020-003 Nov 30, 2022 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Zydus Pharms DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204020-001 Oct 11, 2017 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
Platinum DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204805-002 May 7, 2019 AB RX No No ⤷  Start Trial ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Desvenlafaxine Succinate (DESVENLAFAXINE SUCCINATE): Market Dynamics and Financial Trajectory

Last updated: April 24, 2026

What products and exposure drive the market for desvenlafaxine succinate?

Desvenlafaxine succinate is an oral, serotonin-norepinephrine reuptake inhibitor (SNRI) marketed for major depressive disorder (MDD). Commercial exposure is concentrated in branded originators plus follow-on generics, with revenue shaped by (1) ongoing patent/market-exclusivity timelines, (2) generic entry and price erosion, and (3) payer formularies and persistence dynamics in MDD.

Commercial revenue architecture (how the market tends to pay)

Revenue typically flows through three levers:

  • Unit volume: prescriptions, refills, and patient persistence in MDD treatment
  • Net price: driven by WAC-to-net rebates/discounts and generic discounts post-entry
  • Portfolio displacement: competition with other SNRIs (and newer antidepressants), plus switching to agents with better payer positioning

Key competitive landscape

Desvenlafaxine competes in MDD against:

  • Other SNRI classes (e.g., venlafaxine and duloxetine depending on geography and formulary)
  • Broader antidepressant classes (SSRIs, atypicals)
  • Adjacent depression pharmacotherapy that can displace SNRI share under formulary management

How do patent and exclusivity dynamics impact revenue trajectory?

Desvenlafaxine succinate’s financial trajectory is dominated by the shift from brand pricing to generic pricing after loss of exclusivity. For investors and R&D strategists, the market model is straightforward:

  • Pre-exclusivity: brand price floors with formulary placement advantages
  • Post-entry: sharp net-price declines and volume redistribution to lower-cost products
  • Steady state generics: revenue stabilizes at lower margins, with growth dependent on total market size, adherence, and competitor displacement

What market dynamics typically govern desvenlafaxine succinate after generic entry?

1) Net price compression

After generic launches, net price typically declines faster than volume can compensate. The result is margin compression that persists even as prescription counts hold up in chronic MDD use.

2) Formulary tiering

Payers often move competing agents into lower tiers, shifting prescriptions. Brand persistence depends on:

  • rebate competitiveness
  • prior authorization requirements
  • step therapy adoption
  • exclusion status

3) Patient switching cycles

MDD treatment is chronic, but switching occurs due to tolerability, dose optimization, and payer policy. Switch rates tend to rise after new formulary events and around seasons with heightened prescribing and renewal activity.

What does a financial trajectory look like for desvenlafaxine succinate?

A defensible trajectory framework for desvenlafaxine succinate after exclusivity loss is:

  • Brand revenue peak window: highest net price before generic pressure
  • Generic entry inflection: volume share reallocates; net revenue declines
  • Post-entry stabilization: unit volumes may remain sizeable while net sales trend lower due to pricing

Directionally expected post-generic path

  • Net sales: declines following entry, then flattens
  • Gross margin: compresses with generic-based competitive benchmarks
  • Operating leverage: weakens as selling and payer contracting spend increases to defend share

Which financial KPIs matter most for investors tracking desvenlafaxine succinate?

Market and commercial KPIs

  • Monthly prescriptions and TRx trend (volume health)
  • Net price per script or average realized price trend (pricing power)
  • Formulary position changes (tier moves, PA adoption)
  • Share vs. class in MDD (SNRIs and broader antidepressant segments)

Corporate financial KPIs (for originators)

  • Revenue contribution from the product line
  • Selling, general and administrative spend efficiency
  • Contracting costs and rebate intensity
  • Cash flow resilience after margin compression

What data sources are used to quantify market share and revenue trajectory?

For a production-grade market and financial trajectory build, analysts generally triangulate:

  • IMS/NPA sales and prescription datasets (or equivalent)
  • Public company segment reporting (originator net sales)
  • Generic launch calendars from regulatory filings
  • Payer formulary and policy datasets for tiering and authorization events

What are the key business implications for R&D and investment decisions?

For R&D

  • Product improvement and lifecycle strategies need to address payer friction and switching resistance.
  • If considering line extensions, the value is usually measured against how much formularies will re-tier or reauthorize.

For investment

  • The dominant risk is net price erosion after generic entry.
  • Upside typically comes from volume resilience, new patient creation, or regained contracting strength against competitors.

What does the market outlook look like under standard dynamics for mature SNRI products?

For a mature, widely genericized MDD SNRI like desvenlafaxine succinate, the outlook typically depends on:

  • stability of MDD patient demand
  • intensity of generic competition
  • payer contracting favorability between equivalent generics
  • competitor share shifts in the SNRI and antidepressant classes

Key Takeaways

  • Desvenlafaxine succinate’s revenue trajectory is structurally shaped by generic entry and net price compression, with unit volume unable to fully offset margin decline post-exclusivity.
  • Market dynamics center on payer formularies, step therapy and prior authorization, and switching behavior in chronic MDD treatment.
  • The investment and R&D lens should prioritize net price per script trends, TRx persistence, and formulary positioning, since these drive the post-entry financial path more than new demand creation.

FAQs

1) What drives revenue changes most for desvenlafaxine succinate after exclusivity?

Net price compression driven by generic competition, with volume often stabilizing slower than price declines.

2) Does desvenlafaxine succinate behave like a typical mature MDD brand post-generic?

Yes. Mature SNRI products usually see an inflection around generic entry and then a lower-margin steady state.

3) What payer policies most influence utilization?

Formulary tier placement, prior authorization, and step therapy requirements.

4) Which metric best predicts financial resilience?

Average realized net price per script and TRx/persistence together, because volume without pricing rarely sustains revenue.

5) What competition most affects desvenlafaxine succinate’s share?

Other antidepressants in MDD, especially SNRIs that can win formulary placement and switching.


References

[1] American Society of Health-System Pharmacists. Desvenlafaxine: Drug Information. ASHP. https://www.ashp.org/
[2] U.S. Food and Drug Administration (FDA). Drug Approval Reports / Product Information for desvenlafaxine-containing products. https://www.fda.gov/Drugs/
[3] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (desvenlafaxine succinate entries). https://www.accessdata.fda.gov/scripts/cder/daf/
[4] EvaluatePharma. Global Use/Market and Sales Analytics (industry benchmarking for branded vs generic trajectories). https://www.evaluate.com/

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.